Cochrane · systematic review · CD013245
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
Sathianathen, NJ, Oestreich, MC, Brown, SJane, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 66.7%High 2 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Abiraterone + ADT versus ADT alone in metastatic, hormone‐sensitive prostate cancer
Population: men with metastatic, hormone‐sensitive prostate cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to death from any cause Abiraterone + ADT vs ADT alone | HR 0.64 [0.56, 0.73] | 2 studies · 2201 participants | High |
Quality of life (Functional Assessment of Cancer Therapy‐prostate [FACT‐P; range 0 to 156; higher values = better quality of life]) measured at 12 months Abiraterone + ADT vs ADT alone | no estimate extracted | 1 study · 838 participants | Moderate Downgraded: risk of bias |
Grades III to V adverse events (severe and life threatening, as per the Common Toxicity Criteria v3.0; ) measured at a median Abiraterone + ADT vs ADT alone | RR 1.34 [1.22, 1.47] | 1 study · 1199 participants | High |
Time to death due to prostate cancer measured at a median Abiraterone + ADT vs ADT alone | HR 0.58 [0.5, 0.68] | 2 studies · 2201 participants | Moderate Downgraded: risk of bias |
Time to disease progression measured at a median Abiraterone + ADT vs ADT alone | HR 0.35 [0.26, 0.49] | 2 studies · 2097 participants | Moderate Downgraded: risk of bias |
Discontinued treatment due to adverse events measured at a median Abiraterone + ADT vs ADT alone | RR 1.5 [1.17, 1.92] | 1 study · 1199 participants | Moderate Downgraded: risk of bias |